Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by AQR Capital Management LLC

AQR Capital Management LLC trimmed its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 3.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,624 shares of the biopharmaceutical company’s stock after selling 3,422 shares during the quarter. AQR Capital Management LLC’s holdings in Amicus Therapeutics were worth $869,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Xponance Inc. raised its stake in Amicus Therapeutics by 5.3% in the second quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 936 shares in the last quarter. American International Group Inc. increased its holdings in shares of Amicus Therapeutics by 0.9% in the 4th quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company’s stock valued at $2,004,000 after acquiring an additional 1,298 shares during the last quarter. Arizona State Retirement System raised its position in shares of Amicus Therapeutics by 2.6% during the 2nd quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock worth $615,000 after acquiring an additional 1,577 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Amicus Therapeutics by 1.1% during the second quarter. Principal Financial Group Inc. now owns 240,813 shares of the biopharmaceutical company’s stock worth $2,389,000 after purchasing an additional 2,737 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Amicus Therapeutics by 6.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 50,471 shares of the biopharmaceutical company’s stock valued at $501,000 after purchasing an additional 2,918 shares in the last quarter.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total value of $87,825.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $10,382,718.34. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 22,500 shares of company stock valued at $244,875 over the last three months. 2.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

FOLD has been the topic of a number of research analyst reports. Morgan Stanley cut their price objective on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Friday. JPMorgan Chase & Co. cut their price target on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday, August 16th. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price objective on shares of Amicus Therapeutics in a research note on Friday, September 20th. StockNews.com raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, October 7th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Amicus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.88.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $10.50 on Friday. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57. The stock has a market capitalization of $3.11 billion, a price-to-earnings ratio of -21.43 and a beta of 0.69. The company has a 50-day simple moving average of $11.11 and a 200-day simple moving average of $10.58. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The firm had revenue of $126.67 million during the quarter, compared to the consensus estimate of $121.21 million. During the same period in the prior year, the business earned ($0.15) EPS. The firm’s revenue was up 34.0% compared to the same quarter last year. On average, analysts predict that Amicus Therapeutics, Inc. will post -0.07 EPS for the current year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.